MirImmunoPharm

MirImmunoPharm is a Russian biotechnology company focused on the development and commercialization of innovative RNA-based antiviral therapies. The company's flagship product, MIR-19, is a site-specific small interfering RNA (siRNA) treatment designed to combat COVID-19 by targeting highly conserved regions of the SARS-CoV-2 genome. Developed in partnership with the Institute of Immunology of the Federal Medical-Biological Agency (FMBA), MirImmunoPharm utilizes a proprietary platform for inhaled and intranasal delivery of oligonucleotide therapeutics. The company maintains manufacturing capabilities to produce complex biotechnological drugs under GMP standards. Its research efforts are directed toward expanding the siRNA platform to address other respiratory viruses and immune-mediated conditions.